OBJECTIVE: Insulin resistance is associated with mitochondrial dysfunction and decreased ATP synthesis. Treatment of individuals with type 2 diabetes mellitus (T2DM) withsodium-glucose transporter 2 inhibitors (SGLT2i) improves insulin sensitivity. However, recent reports have demonstrated development of ketoacidosis in subjects with T2DM treated with SGLT2i. The current study examined the effect of improved insulin sensitivity with dapagliflozin on 1) mitochondrial ATP synthesis and 2) substrate oxidation rates and ketone production. RESEARCH DESIGN AND METHODS: The study randomized 18 individuals with T2DM to dapagliflozin (n = 9) orplacebo (n = 9). Before and after 2 weeks, subjects received an insulin clamp with tritiated glucose, indirect calorimetry, and muscle biopsies. RESULTS:Dapagliflozin reduced fasting plasma glucose (167 ± 13 to 128 ± 6 mg/dL) and increased insulin-stimulated glucose disposal by 36% (P < 0.01). Glucose oxidation decreased (1.06 to 0.80 mg/kg ⋅ min, P < 0.05), whereas nonoxidative glucose disposal (glycogen synthesis) increased (2.74 to 4.74 mg/kg ⋅ min, P = 0.03). Dapagliflozin decreased basal glucose oxidation and increased lipid oxidation and plasma ketone concentration (0.05 to 0.19 mmol/L, P < 0.01) in association with an increase in fasting plasma glucagon (77 ± 8 to 94 ± 13, P < 0.01). Dapagliflozin reduced the ATP synthesis rate, which correlated with an increase in plasma ketone concentration. CONCLUSIONS:Dapagliflozin improved insulin sensitivity and caused a shift from glucose to lipid oxidation, which, together with an increase in glucagon-to-insulin ratio, provide the metabolic basis for increased ketone production.
RCT Entities:
OBJECTIVE:Insulin resistance is associated with mitochondrial dysfunction and decreased ATP synthesis. Treatment of individuals with type 2 diabetes mellitus (T2DM) with sodium-glucose transporter 2 inhibitors (SGLT2i) improves insulin sensitivity. However, recent reports have demonstrated development of ketoacidosis in subjects with T2DM treated with SGLT2i. The current study examined the effect of improved insulin sensitivity with dapagliflozin on 1) mitochondrial ATP synthesis and 2) substrate oxidation rates and ketone production. RESEARCH DESIGN AND METHODS: The study randomized 18 individuals with T2DM to dapagliflozin (n = 9) or placebo (n = 9). Before and after 2 weeks, subjects received an insulin clamp with tritiated glucose, indirect calorimetry, and muscle biopsies. RESULTS:Dapagliflozin reduced fasting plasma glucose (167 ± 13 to 128 ± 6 mg/dL) and increased insulin-stimulated glucose disposal by 36% (P < 0.01). Glucose oxidation decreased (1.06 to 0.80 mg/kg ⋅ min, P < 0.05), whereas nonoxidative glucose disposal (glycogen synthesis) increased (2.74 to 4.74 mg/kg ⋅ min, P = 0.03). Dapagliflozin decreased basal glucose oxidation and increased lipid oxidation and plasma ketone concentration (0.05 to 0.19 mmol/L, P < 0.01) in association with an increase in fasting plasma glucagon (77 ± 8 to 94 ± 13, P < 0.01). Dapagliflozin reduced the ATP synthesis rate, which correlated with an increase in plasma ketone concentration. CONCLUSIONS:Dapagliflozin improved insulin sensitivity and caused a shift from glucose to lipid oxidation, which, together with an increase in glucagon-to-insulin ratio, provide the metabolic basis for increased ketone production.
Authors: Muhammad A Abdul-Ghani; Florian L Muller; Yuhong Liu; Alberto O Chavez; Bogdan Balas; Pengou Zuo; Zhi Chang; Devjit Tripathy; Rucha Jani; Marjorie Molina-Carrion; Adriana Monroy; Franco Folli; Holly Van Remmen; Ralph A DeFronzo Journal: Am J Physiol Endocrinol Metab Date: 2008-07-01 Impact factor: 4.310
Authors: Landon Brown; Alison Luciano; Jane Pendergast; Pascale Khairallah; Cheryl A M Anderson; James Sondheimer; L Lee Hamm; Ana C Ricardo; Panduranga Rao; Mahboob Rahman; Edgar R Miller; Daohang Sha; Dawei Xie; Harold I Feldman; John Asplin; Myles Wolf; Julia J Scialla Journal: Am J Kidney Dis Date: 2019-03-22 Impact factor: 8.860
Authors: Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim Journal: J Cardiovasc Transl Res Date: 2022-03-15 Impact factor: 4.132
Authors: Stephanie Kullmann; Julia Hummel; Robert Wagner; Corinna Dannecker; Andreas Vosseler; Louise Fritsche; Ralf Veit; Konstantinos Kantartzis; Jürgen Machann; Andreas L Birkenfeld; Norbert Stefan; Hans-Ulrich Häring; Andreas Peter; Hubert Preissl; Andreas Fritsche; Martin Heni Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112